Pharmosa Biopharm (ROCO:6875) Long-Term Debt: NT$0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
12 GF Score
Price NT$33.15
! 1 Warning Sign
View Full Analysis

What is Pharmosa Biopharm Long-Term Debt?

Pharmosa Biopharm ROCO:6875 +0.91% 12 Long-Term Debt is NT$0.00 Mil as of Dec. 2025. GuruFocus rates ROCO:6875 with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Pharmosa Biopharm's Long-Term Debt for the quarter that ended in Dec. 2025 was NT$0.00 Mil.

Pharmosa Biopharm's annual Long-Term Debt declined from Dec. 2023 (NT$1.19 Mil) to Dec. 2024 (NT$0.00 Mil) but then stayed the same from Dec. 2024 (NT$0.00 Mil) to Dec. 2025 (NT$0.00 Mil).

Pharmosa Biopharm  (ROCO:6875) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Pharmosa Biopharm Long-Term Debt Related Terms

Pharmosa Biopharm Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Long-Term Debt Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 5.96 2.45 1.19 0.00 0.00

Pharmosa Biopharm Quarterly Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6875
12GF Score
Pharmosa Biopharm Inc ROCO:6875
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of NT$0.00 Mil mean?
Pharmosa Biopharm (ROCO:6875) has a Long-Term Debt of NT$0.00 Mil as of Dec. 2025.
Is Pharmosa Biopharm's Long-Term Debt too high?
Pharmosa Biopharm's current Long-Term Debt is NT$0.00 Mil. Overall, Pharmosa Biopharm has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Long-Term Debt compare to VRTX and REGN?
Pharmosa Biopharm's Long-Term Debt of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Pharmosa Biopharm's current Long-Term Debt is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Pharmosa Biopharm (ROCO:6875) has a current Long-Term Debt of NT$0.00 Mil. The current Long-Term Debt is NT$0.00 Mil. Pharmosa Biopharm's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Long-Term Debt is NT$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
12GF Score

Get the complete analysis for ROCO:6875

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.15
Price